Last update 08 May 2025

PKD1 x SHANK3

Basic Info

Related Targets
PKD1SHANK3

Related

1
Drugs associated with PKD1 x SHANK3
PYC-003
Target
PKD1 x SHANK3
Mechanism
PKD1 inhibitors [+2]
Active Org.
PYC Therapeutics Ltd.PYC Therapeutics Ltd.
Originator Org.
PYC Therapeutics Ltd.PYC Therapeutics Ltd.
Active Indication
Polycystic Kidney, Autosomal Dominant [+1]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
1
Clinical Trials associated with PKD1 x SHANK3
NCT06714006
/ RecruitingPhase 1
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenously Administered PYC-003, a Peptide-phosphorodiamidate Morpholino Oligonucleotide Conjugate, in Healthy Adult Participants and Adult Participants With Confirmed PKD1 Mutation-associated Autosomal Dominant Polycystic Kidney Disease
100 Clinical Results associated with PKD1 x SHANK3
Login to view more data
100 Translational Medicine associated with PKD1 x SHANK3
Login to view more data
0 Patents (Medical) associated with PKD1 x SHANK3
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free